Verrica Pharmaceuticals VRCA
NASDAQ VRCA
$4.38 -0.13 (-2.88%)
At close: Oct 2, 2026 · 4:00 PM EDT

Verrica Pharmaceuticals (VRCA) Gains from Sales and Divestitures (2023 - 2025)

Updated

Verrica Pharmaceuticals (VRCA) reported Gains from Sales and Divestitures of -$246,000 for FY2025, compared with -$83,000 in FY2024.

Analysis

Verrica Pharmaceuticals (VRCA) Gains from Sales and Divestitures (2023 - 2025) Analysis & Trends

  • According to Business Quant data, Gains from Sales and Divestitures came in at -$83,000 in FY2024 and -$2.54 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Verrica Pharmaceuticals 75.24 Mn -7.80 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -68,000.00
Dec 31, 2024 58,000.00
Dec 31, 2023 -2.48 Mn
Sep 30, 2023 -61,000.00
API Access

Verrica Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=VRCA&period=max&api_key=YOUR_API_KEY